XML 80 R63.htm IDEA: XBRL DOCUMENT
v3.19.1

Collaboration and License Agreements (Details) € in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Oct. 31, 2018 USD ($) | Nov. 30, 2017 USD ($) | Oct. 31, 2017 USD ($) | Aug. 31, 2016 USD ($) | Nov. 30, 2015 USD ($) milestone | Oct. 31, 2014 USD ($) | Oct. 31, 2014 EUR (€) | Jul. 31, 2005 USD ($) | Sep. 30, 2018 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) job
Collaboration and License Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |  |
Sanofi Upfront Payment |  |  |  |  | $ 300,000,000 |  |  |  |  |  |  |
Sanofi Development Milestones |  |  |  |  | $ 110,000,000 |  |  |  |  |  |  |
Number of development milestones | milestone |  |  |  |  | 4 |  |  |  |  |  |  |
Sanofi Regulatory Milestones |  |  |  |  | $ 220,000,000 |  |  |  |  |  |  |
Number of regulatory milestones | milestone |  |  |  |  | 4 |  |  |  |  |  |  |
Sanofi Outcomes Study Milestone |  |  |  |  | $ 100,000,000 |  |  |  |  |  |  |
Sanofi Sales Milestone Payments |  |  |  |  | $ 990,000,000 |  |  |  |  |  |  |
Number of commercial milestones | milestone |  |  |  |  | 6 |  |  |  |  |  |  |
Royalties percentage |  |  |  |  | 40.00% |  |  |  |  |  |  |
Funded commercialization costs |  |  |  |  | 40.00% |  |  |  |  |  |  |
Development costs period |  |  |  |  | 3 years |  |  |  |  |  |  |
Sanofi Development Costs Funded by Lexicon Maximum Amount |  |  |  |  | $ 100,000,000 |  |  |  |  |  |  |
Expiration period |  |  |  |  | 10 years |  |  |  |  |  |  |
Sanofi Revenue Allocated to Development Deliverable |  |  |  |  | $ 113,800,000 |  |  |  |  |  |  |
Sanofi Revenue Allocated to License Deliverable |  |  |  |  | 126,800,000 |  |  |  |  |  |  |
Sanofi Revenue Recognized |  |  |  |  |  |  |  |  |  | $ 33,200,000 | $ 60,100,000 | $ 71,300,000
Sanofi Sales of Clinical Trial Materials |  |  |  |  |  |  |  |  |  |  | 1,900,000 | 6,300,000
Sanofi Revenue Allocated to Funding Deliverable |  |  |  |  | $ 59,400,000 |  |  |  |  |  |  |
Sanofi revenue from filing performance_LXRX |  |  |  |  |  |  |  |  |  | 8,600,000 |  |
Ipsen Total Payments To Date |  |  |  |  |  |  |  |  |  | 45,000,000 |  |
Ipsen Total Upfront Payments |  |  |  |  |  | $ 24,500,000 |  |  |  |  |  |
Ipsen Milestone Payment Received | $ 1,300,000 | $ 3,800,000 | $ 3,800,000 | $ 6,400,000 |  |  |  |  | $ 5,100,000 |  |  |
Ipsen Revenue Allocated to License Deliverable |  |  |  |  |  | 21,200,000 |  |  |  |  | 1,400,000 |
Ipsen Maximum Regulatory And Commercial Milestones |  |  |  |  |  | 11,800,000 |  |  |  |  |  |
Ipsen Revenue Allocated to Development Deliverable |  |  |  |  |  | 1,700,000 |  |  |  |  |  |
Ipsen Revenue Allocated to Committee Deliverable |  |  |  |  |  | $ 100,000 |  |  |  |  |  |
Ipsen Revenue Recognized |  |  |  |  |  |  |  |  |  | 4,600,000 | 16,200,000 | $ 7,200,000
Ipsen Royalty Income_LXRX |  |  |  |  |  |  |  |  |  | 300,000 | 100,000 |
Ipsen product sales |  |  |  |  |  |  |  |  |  | 1,600,000 | $ 800,000 |
Ipsen Maximum Sales Milestones | € |  |  |  |  |  |  | € 72 |  |  |  |  |
TIGM Maximum Exposure |  |  |  |  |  |  |  |  |  | 14,200,000 |  |
TX Enterprise Fund Award |  |  |  |  |  |  |  | $ 35,000,000 |  |  |  |
TX Enterprise Fund Award to Texas AM University System |  |  |  |  |  |  |  | $ 15,000,000 |  |  |  |
Aggregate number of new jobs | job |  |  |  |  |  |  |  |  |  |  |  | 1,616
TIGM Per Job Payment Amount |  |  |  |  |  |  |  |  |  | $ 2,415 |  |

X
- Definition Collaboration and License Agreements [Abstract] + References No definition available. + Details
Name: | lxrx_CollaborationAndLicenseAgreementsAbstract
Namespace Prefix: | lxrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments. + References No definition available. + Details
Name: | lxrx_IpsenMaximumRegulatoryAndCommercialMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments. + References No definition available. + Details
Name: | lxrx_IpsenMaximumSalesMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period. + References No definition available. + Details
Name: | lxrx_IpsenMilestonePaymentReceived
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoLicenseDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period. + References No definition available. + Details
Name: | lxrx_IpsenRevenueRecognized
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S. + References No definition available. + Details
Name: | lxrx_IpsenRoyaltyIncome_LXRX
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date. + References No definition available. + Details
Name: | lxrx_IpsenTotalPaymentsToDate
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement. + References No definition available. + Details
Name: | lxrx_IpsenTotalUpfrontPayments
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen. + References No definition available. + Details
Name: | lxrx_Ipsenproductsales
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number Of Positions Created, Inception To Date + References No definition available. + Details
Name: | lxrx_NumberOfPositionsCreatedInceptionToDate
Namespace Prefix: | lxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage + References No definition available. + Details
Name: | lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Development Costs Period + References No definition available. + Details
Name: | lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod
Namespace Prefix: | lxrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Expiration Period + References No definition available. + Details
Name: | lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod
Namespace Prefix: | lxrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones + References No definition available. + Details
Name: | lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones + References No definition available. + Details
Name: | lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones + References No definition available. + Details
Name: | lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage + References No definition available. + Details
Name: | lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs. + References No definition available. + Details
Name: | lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients. + References No definition available. + Details
Name: | lxrx_SanofiDevelopmentMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval. + References No definition available. + Details
Name: | lxrx_SanofiOutcomesStudyMilestone
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe. + References No definition available. + Details
Name: | lxrx_SanofiRegulatoryMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable. + References No definition available. + Details
Name: | lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable. + References No definition available. + Details
Name: | lxrx_SanofiRevenueAllocatedtoFundingDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable. + References No definition available. + Details
Name: | lxrx_SanofiRevenueAllocatedtoLicenseDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period. + References No definition available. + Details
Name: | lxrx_SanofiRevenueRecognized
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement. + References No definition available. + Details
Name: | lxrx_SanofiSalesMilestonePayments
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the sales of clinical trial materials recognized in the period. + References No definition available. + Details
Name: | lxrx_SanofiSalesofClinicalTrialMaterials
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement. + References No definition available. + Details
Name: | lxrx_SanofiUpfrontPayment
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sanofi revenue from filing performance_LXRX - represents revenue earned when Lexicon performed services relating to the filing and application of sotagliflozin to the FDA. Sanofi and Lexicon entered into a contract modification for this specific performance obligation. + References No definition available. + Details
Name: | lxrx_Sanofirevenuefromfilingperformance_LXRX
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Under the Texas Enterprise Fund award, Lexicon has a maximum aggregate exposure if Lexicon fails to create the specified number of jobs or obtain credits. + References No definition available. + Details
Name: | lxrx_TigmMaximumExposure
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Under the terms of the Texas Enterprise Fund award, subject to certain credits, if Lexicon fails to create the specified number of jobs, the state may require Lexicon to repay $2,415 for each job Lexicon falls short. + References No definition available. + Details
Name: | lxrx_TigmPerJobPaymentAmount
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition In July 2005, Lexicon received a $35.0 million award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine using Lexicon's proprietary gene trappying technology, which Lexicon completed in 2007. + References No definition available. + Details
Name: | lxrx_TxEnterpriseFundAward
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In July 2005, the Texas Enterprise Fund awarded $15.0 million to the Texas A&M University System for the creation of facilities and infrastructure to house the library. + References No definition available. + Details
Name: | lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration